Skip to main content
. 2011 Nov;13(11):1058–1068. doi: 10.1593/neo.111112

Figure 4.

Figure 4

G6 provides therapeutic benefit to the bone marrow of Jak2-V617F MPN mice by alleviating megakaryocytic and myeloid hyperplasia. (A) Representative bone marrow sections showing the effect of G6 on megakaryocytic hyperplasia. (B) Average number of megakaryocytes per HPF plotted as a function of treatment group. (C) M/E ratios plotted as a function of treatment group. *P < .05 and **P < .001 versus vehicle treated.